ARBUTUS BIOPHARMA CORP. REGISTERED SHARES O.N. ehem Tekmira Pharmaceuticals vor dem Durchbruch? (Seite 549)
eröffnet am 07.08.14 10:02:11 von
neuester Beitrag 07.05.24 10:30:38 von
neuester Beitrag 07.05.24 10:30:38 von
Beiträge: 11.000
ID: 1.197.187
ID: 1.197.187
Aufrufe heute: 92
Gesamt: 1.136.591
Gesamt: 1.136.591
Aktive User: 0
ISIN: CA03879J1003 · WKN: A14XMD · Symbol: I9DN
2,6380
EUR
+0,84 %
+0,0220 EUR
Letzter Kurs 07.05.24 Tradegate
Neuigkeiten
07.05.24 · globenewswire  |
02.05.24 · globenewswire |
02.05.24 · globenewswire |
18.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4000 | +49,07 | |
| 1,1600 | +40,52 | |
| 1,3670 | +25,30 | |
| 1,0340 | +23,54 | |
| 6,7100 | +22,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,5000 | -13,79 | |
| 1,3800 | -20,80 | |
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 |
Beitrag zu dieser Diskussion schreiben
Feedback
Hallo ick höre dir pfeifen
wieder verkaufen die Insider Ihre Aktien - alleine bis Mitte August wieder über 100 000 Akien Also entweder brauchen die ganz dringend Geld - oder glauben nicht wirklich an den eigenen Erfolg!? Seit März verkaufen die Ihre Aktien als gäbe es kein Morgen mehr...........
Moderna | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1315946-neustebe…
wieder verkaufen die Insider Ihre Aktien - alleine bis Mitte August wieder über 100 000 Akien Also entweder brauchen die ganz dringend Geld - oder glauben nicht wirklich an den eigenen Erfolg!? Seit März verkaufen die Ihre Aktien als gäbe es kein Morgen mehr...........
Moderna | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1315946-neustebe…
Antwort auf Beitrag Nr.: 64.794.157 von ThumsUp am 18.08.20 07:55:12Deine Beiträge sind einfach immer lesenswert und informativ dafür einen Daumen
Antwort auf Beitrag Nr.: 64.794.157 von ThumsUp am 18.08.20 07:55:12Ausgezeichnet rechechiert 👍 Ich errinere mich an Pharmaset die Aktie tuempelte bei 10 Dollar dahin
und von einem Tag auf den anderen stieg sie auf 100 Dollar.
Der Kurs von ABUS hat sich in den letzten Tagen beruhigt wie die Ruhe vor dem Sturm ?
Kurzfristig wenn Arbustus geschluckt wird koennen wir uns mit einem schoenen Gewinn verabschieden,
Laengerfristig mit Blockbuster Hepatitis-B wuerde unser Gewinn vermehrfacht dann steig Arbustus
auf ueber 150 Dollar.
und von einem Tag auf den anderen stieg sie auf 100 Dollar.
Der Kurs von ABUS hat sich in den letzten Tagen beruhigt wie die Ruhe vor dem Sturm ?
Kurzfristig wenn Arbustus geschluckt wird koennen wir uns mit einem schoenen Gewinn verabschieden,
Laengerfristig mit Blockbuster Hepatitis-B wuerde unser Gewinn vermehrfacht dann steig Arbustus
auf ueber 150 Dollar.
jemand hat einen beitrag geliked, ab sofort trage ich voller stolz die mir verliehene "erklärer"-medaille.
hat jemand ein taschentuch...
ich wurde per nachricht angefragt, was hier genau sache ist, und erkläre dazu:ich weiss es auch nicht. im yahwee-board, wo jede menge info-schrott zu finden ist, tauchen gelegentlich auch lesenswerte beiträge auf. einen habe ich kopiert, zum lesen hier.
für den fierker feuerstein:einfach durch google-t jagen.
https://finance.yahoo.com/quote/abus/community?p=ABUS
"I'm a shareholder of both and would love to see a buyout! So I sent this to Moderna's mgmt.
Please forward to Management:
As a shareholder of Moderna, I did my extensive research on recent patent loss to Arbutus as I had no idea that there was a patent issue whatsoever when I purchased Moderna shares. As one of your shareholders, I feel that Moderna could create a much higher shareholder value based on the following research.
Arbutus “spun” out their LPN technology in 2018 and created a joint company with Roivant to form Genevant whereby Arbutus would have 40% stake but kept their Hep B research for commercialization. Genevant sublicensed this technology to BioNTech who has partnered with Pfizer for the Covid vaccine project BNT162 vaccine. In addition, Curevac who recently went public who now has a market cap of $13.6 Billion has also sublicensed the LPN technology from Acuitas who I thought Moderna had sublicensed agreement with. Acuitas in-fact has sublicense agreement with Arbutus but that sublicense is limited based on 2018 settlement with Arbutus.
I did more research on Arbutus and their Chief Scientific Officer is NONE other than Dr. Michael Sofia. That name is very familiar with me because I was a shareholder of Pharmasset back in 2010 and Gilead purchased Pharmasset for $11 Billion in 2012. Dr. Sofia was responsible for the discovery of Sofosbuvir (cure for Hep C) and when Gilead got the FDA approval, their first year of sales in 2015 soared to $10.3 Billion (world’s best-selling drug in the first year). Dr. Sofia in May of this year received the prestigious University of Edinburgh Cameron Prize for Therapeutics for finding the cure for Hep C. Arbutus has promising cure for Hep B and Dr. Sofia being the CSO, I have no doubt that they will find a cure yet again that would be another blockbuster drug to come to market. Dr. Sofia has a proven track record and speaks for itself.
While I love the fact that Moderna’s shares have gone up significantly, it could and should be worth much more based on the pipeline of promising drugs and vaccine for Covid. I’m not as smart as Moderna’s management and maybe management has already done their due diligence but why would Moderna not just buyout Arbutus? With the buyout, Moderna would not have to pay millions and possible billions in royalty payments to Genevant and would also receive royalties from BioNTech/Pfizer should their Covid vaccine come to market as 40% stakeholder of Genevant (Genevant also has promising drug discovery pipeline as well). In addition, should Curevac’s vaccine come to market for their Covid vaccine, there would be additional royalties. I have not done my DD on the licensing by Curevac but I’m sure it will be in hundreds of millions in royalties. Moderna then would also have access to a possible Hep B cure which is a multi-billion-dollar market as well. It took many tries and approx.. 5 yrs for Dr. Sofia to get FDA approval for Hep C cure and he will do it again for Hep B cure at a much faster rate with their technology.
While Moderna’s market cap has significantly increased, why not leverage that to buyout a $300 million market cap company literally cents on the dollar while you can. I strongly feel that this patent loss has put a cap on Moderna’s stock and should Moderna buyout Arbutus, that cap will be lifted which would significantly enhance shareholder value. I have no knowledge that other companies are looking at Arbutus but if an individual investor like myself can come to this conclusion, I’m sure other big pharma companies with deep pockets who can pay cash for Arbutus is now looking to do the same. Should one of these big pharma’s acquire Arbutus, that would mean even higher royalty payments for Moderna as they will want a premium for their acquisition costs of Arbutus.
In full disclosure, I am a shareholder of Moderna as well as Arbutus (just recently). Thank you"
hat jemand ein taschentuch...
ich wurde per nachricht angefragt, was hier genau sache ist, und erkläre dazu:ich weiss es auch nicht. im yahwee-board, wo jede menge info-schrott zu finden ist, tauchen gelegentlich auch lesenswerte beiträge auf. einen habe ich kopiert, zum lesen hier.
für den fierker feuerstein:einfach durch google-t jagen.
https://finance.yahoo.com/quote/abus/community?p=ABUS
"I'm a shareholder of both and would love to see a buyout! So I sent this to Moderna's mgmt.
Please forward to Management:
As a shareholder of Moderna, I did my extensive research on recent patent loss to Arbutus as I had no idea that there was a patent issue whatsoever when I purchased Moderna shares. As one of your shareholders, I feel that Moderna could create a much higher shareholder value based on the following research.
Arbutus “spun” out their LPN technology in 2018 and created a joint company with Roivant to form Genevant whereby Arbutus would have 40% stake but kept their Hep B research for commercialization. Genevant sublicensed this technology to BioNTech who has partnered with Pfizer for the Covid vaccine project BNT162 vaccine. In addition, Curevac who recently went public who now has a market cap of $13.6 Billion has also sublicensed the LPN technology from Acuitas who I thought Moderna had sublicensed agreement with. Acuitas in-fact has sublicense agreement with Arbutus but that sublicense is limited based on 2018 settlement with Arbutus.
I did more research on Arbutus and their Chief Scientific Officer is NONE other than Dr. Michael Sofia. That name is very familiar with me because I was a shareholder of Pharmasset back in 2010 and Gilead purchased Pharmasset for $11 Billion in 2012. Dr. Sofia was responsible for the discovery of Sofosbuvir (cure for Hep C) and when Gilead got the FDA approval, their first year of sales in 2015 soared to $10.3 Billion (world’s best-selling drug in the first year). Dr. Sofia in May of this year received the prestigious University of Edinburgh Cameron Prize for Therapeutics for finding the cure for Hep C. Arbutus has promising cure for Hep B and Dr. Sofia being the CSO, I have no doubt that they will find a cure yet again that would be another blockbuster drug to come to market. Dr. Sofia has a proven track record and speaks for itself.
While I love the fact that Moderna’s shares have gone up significantly, it could and should be worth much more based on the pipeline of promising drugs and vaccine for Covid. I’m not as smart as Moderna’s management and maybe management has already done their due diligence but why would Moderna not just buyout Arbutus? With the buyout, Moderna would not have to pay millions and possible billions in royalty payments to Genevant and would also receive royalties from BioNTech/Pfizer should their Covid vaccine come to market as 40% stakeholder of Genevant (Genevant also has promising drug discovery pipeline as well). In addition, should Curevac’s vaccine come to market for their Covid vaccine, there would be additional royalties. I have not done my DD on the licensing by Curevac but I’m sure it will be in hundreds of millions in royalties. Moderna then would also have access to a possible Hep B cure which is a multi-billion-dollar market as well. It took many tries and approx.. 5 yrs for Dr. Sofia to get FDA approval for Hep C cure and he will do it again for Hep B cure at a much faster rate with their technology.
While Moderna’s market cap has significantly increased, why not leverage that to buyout a $300 million market cap company literally cents on the dollar while you can. I strongly feel that this patent loss has put a cap on Moderna’s stock and should Moderna buyout Arbutus, that cap will be lifted which would significantly enhance shareholder value. I have no knowledge that other companies are looking at Arbutus but if an individual investor like myself can come to this conclusion, I’m sure other big pharma companies with deep pockets who can pay cash for Arbutus is now looking to do the same. Should one of these big pharma’s acquire Arbutus, that would mean even higher royalty payments for Moderna as they will want a premium for their acquisition costs of Arbutus.
In full disclosure, I am a shareholder of Moderna as well as Arbutus (just recently). Thank you"
Antwort auf Beitrag Nr.: 64.790.353 von Tamidor_WD am 17.08.20 18:48:40Da gebe ich dir Recht. Ich sehe 2 von 3 eh wieder stark fallen, wenn nicht sogar alle. Dennoch finde ich die Situation von Arbutus sehr interessant.
Trading Spotlight
Das erklärt nicht warum Curevac explodiert, die anderen Impfstoffwerte schon explodiert sind und Arbutus dümpelt.
Antwort auf Beitrag Nr.: 64.789.396 von Tamidor_WD am 17.08.20 17:44:31Klar gibt es einen Haken. Kein impstoff kein Geld.
Nicht umsonst sind hier ganz große Adressen investiert.
Das ist genau die Frage, wir scheinen hier im Forum die einzigen zu sein, die glauben, dass Arbutus davon profitiert und daher massiv unterbewertet ist. Oft zeigt sich später ein Haken, der dafür sorgt, dass der Kurs nicht höher geht. Ich werde auch immer skeptischer.
Antwort auf Beitrag Nr.: 64.787.515 von blue-moon am 17.08.20 15:48:40deine zeilen in Gottes Ohr. ich bin geduldig, aber wenn es bei alles news immer noch bergab geht, verliere ich den Glauben. Alle grossen BionTech, Moderna jetzt noch Curevac arbeieten mit dem Patent von ABUS. Für mich langsam zu hoch das ABUS das so hin nimmt
Durchsuchen
ARBUTUS BIOPHARMA CORP. REGISTERED SHARES O.N. ehem Tekmira Pharmaceuticals vor dem Durchbruch?
